Advanced Oncotherapy Regulatory News (AVO)

 25 July 2014

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

AGM Statement

Advanced Oncotherapy (AIM: AVO), the developer of innovative radiation technology for cancer treatment, will hold its Annual General Meeting at the offices of Lord David Evans at 184-192 Drummond Street, London NW1 3HP on Friday 25 July 2014 at 10am. At the meeting Sanjeev Pandya, Chief Executive Officer of Advanced Oncotherapy, will make the following statement:

I am very pleased to say that we have an accelerated delivery timescale for the delivery of a key Radio Frequency Quadripole (RFQ) unit from CERN. The RFQ serves as the injector to the subsequent parts of the accelerator of the proton beam. Our pipeline of prospective clients is growing, and we're delighted to announce we have identified two additional locations in South East Asia; three in the Middle East; and two in North America. Our Product Development Committee has reported that it expects the FDA approval process for our LIGHT technology to be concluded within the next 15 months.

For further information contact:

About Advanced Oncotherapy

Vision:

To advance patients' clinical treatments and improve their everyday lives by harnessing innovative science and focusing it to develop the most effective and affordable cancer treatments.

Mission:

To facilitate the wider use of radiation with protons for treating all forms of cancerous tumours by commercialising novel technologies inspired by CERN and the Large Hadron Collider.

Key corporate messages:

AVO's team based at CERN near Geneva focuses on the development of a proprietary proton system called Linac Image Guided Hadron Technology (LIGHT). This LIGHT system accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

AVO is a provider of proton radiotherapy that harnesses the best in modern technology. As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.

AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care.

AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK from Spire Healthcare and BMI Healthcare Hospitals.

Through its shareholding and collaboration with Advanced Proton Solutions (APS), AVO can offer a complete turnkey solution to the design installation and operation of its LIGHT proton system for healthcare providers. This is attractive to potential purchasers and has led to its involvement in the development of the first comprehensive proton beam therapy centre in London to treat both NHS and private patients.

For more information, please visit http://www.avoplc.com